REGENERON PHARMACEUTICALS, INC. (REGN) Income statement
Top 20 of 27 line items reported by REGN · 250+ in the full API →
REGENERON PHARMACEUTICALS, INC. (REGN) · Income Statement
Consolidated Statements of Operations
Annual · In millions USD, except per-share data · Latest filed Feb 4, 2026 · FY ends Dec 31
| Fiscal Years Ended | |||||
|---|---|---|---|---|---|
FY2025 Dec 31, 2025 | FY2024 Dec 31, 2024 | FY2023 Dec 31, 2023 | FY2022 Dec 31, 2022 | Trend | |
| Total Revenue | $14,343 | $14,202 | $13,117 | $12,173 | |
| Cost of Revenue | 2,101 | 1,971 | 1,816 | 1,560 | |
| Gross Profit | $12,242 | $12,232 | $11,301 | $10,613 | |
| Other Operating Expenses | 8,664 | 8,241 | 7,254 | 5,874 | |
| Total Operating Expenses | 10,765 | 10,211 | 9,070 | 7,434 | |
| Operating Income | $3,578 | $3,991 | $4,047 | $4,739 | |
| EBIT (Earnings Before Interest & Tax) | 3,578 | 3,991 | 4,047 | 4,739 | |
| Add: Depreciation & Amortization | 544 | 483 | 421 | 341 | |
| EBITDA (Non-GAAP) | $4,122 | $4,474 | $4,468 | $5,080 | |
| Interest Expense | -44 | -55 | -73 | -59 | |
| Investment Gains (Losses) | 956 | 118 | (236) | — | |
| Non-Operating Income (Expense) | $1,653 | $789 | $152 | $120 | |
| Income Before Taxes (EBT) | $5,231 | $4,780 | $4,199 | $4,859 | |
| Provision for Income Taxes | 726 | 367 | 246 | 520 | |
| Effective Tax Rate | 13.9% | 7.7% | 5.9% | 10.7% | |
| Net Income | $4,505 | $4,413 | $3,954 | $4,338 | |
| Shares Outstanding | 105 | 108 | 107 | 107 | |
| Diluted Shares Outstanding | 109 | 115 | 114 | 114 | |
| Diluted Earnings Per Share | $41.48 | $38.34 | $34.77 | $38.22 | |
| Gross Margin | 85.4% | 86.1% | 86.2% | 87.2% | |
7 more line items available via the API
Research & DevelopmentSales, General & AdministrativeGain (Loss) on Equity SecuritiesBasic Earnings Per ShareOperating MarginOther OpEx MarginNet Margin
Ask your agent:
get_financialsAPIGET /api/v1/companies/REGN/income-statement?period=annual&years=8Docs →